Immunomodulation by muramyl peptides: Recent developments

Biochemical characterization of glucosaminylmuramyldipeptide binding sites of murine macrophages

By using radioligand analysis, murine peritoneal macrophages were shown to express several hundred high-affinity cell surface GMDP-binding sites (Ka 350 pM). Photoaffinity labeling followed by SDS-PAGE enabled us to identify 32-34 and 38 kDa proteins inside these cells that bound GMDP specifically.

Muramyl peptide-binding sites are located inside target cells

Using flow cytometry and fluorescence polarization analysis, specific muramyl peptide-binding sites were shown to be located inside T-lymphocytes, macrophages and neuroblastoma cells, but not inside B-cells. No binding sites were found on the cell surface. The number of binding sites for each cell type was determined. Two types of binding sites were observed for myelomonocytic WEHI-3 cells with Kd values of 21 and 540 nM. Inhibition analysis demonstrated that for effective binding, an intact glycopeptide molecule and D-configuration of isoglutamine residue are important.

Photoaffinity labelling of macrophages and B-lymphocytes using 125I-labelled aryl-azide derivatives of muramyldipeptide

Two 125I-labelled aryl-azide derivatives of MDP have been synthesized. Photoaffinity labelling experiments demonstrated cell surface binding sites for muramylpeptides on activated B-lymphocytes and intracellular muramylpeptides binding protein(s) of 40-45 kD in rat alveolar macrophages.

Stimulation of cell proliferation in rabbits by MTP-PE, a lipophilic muramyl peptide

The in vivo effect of the lipophilic muramyl peptide MTP-PE on the proliferation of blood cells and various tissues of the rabbit was studied by means of 3H-thymidine. Animals were killed up to 120 h after one or two i.v. injections of MTP-PE (10 mg/kg). MTP-PE caused a drastic effect on white blood cells: (1) neutropenia and lymphocytopenia occurring within 5 h was followed by leukocytosis of neutrophils and their juvenile forms by 24 h and thereafter, (2) within 24 h the number of prelabelled, i.e. recently regenerated, mononuclear cells in the bone marrow and the vascular system of various tissues increased approximately threefold, and (3) within 48 h the concentration of proliferating monocytic cells (1-h pulse labelling) rose to maximum levels of up to 20-fold in the lumina of blood vessels, particularly in capillaries of many organs. The number of proliferating cells also increased in the adventitia of medium and small arteries with a maximum at 48 h, whereas this occurred only later in the media and hardly at all in the intima. Thus, these proliferating, apparently monocytic cells are blood derived, and migrate into the tissue within 24 h after MTP-PE administration. In addition, proliferation in the epithelium of the bile ducts and oesophagus was also stimulated with a maximum at 24 h after MTP-PE. In contrast, enhanced proliferation occurred more slowly and to a lesser extent in hepatocytes, hepatic interstitial cells, and renal epithelial cells, consistent with a regenerative process after an inflammatory or toxic event.

Synthesis, mass spectral characterization and immunoadjuvant activity of some novel lipophilic derivatives of muramyl dipeptides

Some novel lipophilic derivatives of N-acetylmuramyl-L-alanyl-D-isoglutamine (MDP) have been prepared and rigorously evaluated by spectroscopic means. Fast atom bombardment and field desorption mass spectrometry provided information about both molecular weight and structural detail. The new MDP derivatives have been tested in guinea pigs for immunoadjuvant activity using egg albumin as the model antigen. Amongst these derivatives, 6-O-[3-(5-cholesten-3 beta-yloxycarbonyl) propionyl]-N-acetylmuramyl-L-alanyl-D-isoglutamine (CSMDP), 6-O-[3-1,2-dipalmitoyl-sn-glycero-3-carbonyl) propionyl]-N-acetylmuramyl-L-alanyl-D-isoglutamine (GSMDP) and N-palmitoyl muramyl-L-alanyl-D-isoglutamine (PMDP) possessed significantly better activity than MDP, as judged by the antigen-specific antibody and delayed hypersensitivity responses in the immunized animals. In addition, CSMDP was found to induce strong delayed hypersensitivity response even in saline. These three active compounds were also tested for their pyrogenic response in rabbits, and were found to be lesser pyrogenic than MDP. Some of these MDP derivatives hold promise as adjuvants in immunization.

Enhancement in anti-Semliki Forest virus activity of ds RNA by a muramyl dipeptide

Antiviral activity of an interferon-inducing mycoviral ds RNA against Semliki Forest virus infection was considerably enhanced by N-palmitoylmuramyl-L-alanyl-D-isoglutamine (PMDP), a new muramyl dipeptide. This enhancement in activity was not due to increased production of interferon, but resulted probably from a PMDP-induced increase in nonspecific resistance to infection. These results indicate that a combined treatment with an interferon inducer and muramyl dipeptide may prove highly useful to control effectively viral infections.

Modulation of helper T-cell activity by macrophage products

Mouse spleen cells cultured with muramyl dipeptide (MDP) release factors (SMF, or splenic macrophage factors) which enhance the in vitro plaque-forming cell (PFC) response to the T-dependent antigen SRBC (sheep red blood cells). The present study substantiates previous results and shows that T cells were the target cells of such conditioned medium. We investigated which T-cell subpopulations had their activities modified by these factors. In the presence of SMF, T cells educated in vivo elicited enhanced PFC responses to both specific educating antigen and an unrelated antigen (during a bystander response). This could indicate that SMF potentiates Th2-cell activity. Moreover, in vivo matured but unprimed thymocytes, which are unable to cooperate with virgin B cells in an in vitro T-dependent response, are able to do so when SMF is added in cooperative cultures. It is concluded that MDP-conditioned medium allows the maturation/differentiation of a subset of T cells to the point where they can be stimulated by the antigen.

Protection of mice against fatal herpes simplex type 2 infection by liposomes containing muramyl tripeptide

Intravenous administration of liposomes containing muramyl tripeptide phosphatidylethanolamine, a lipophilic derivative of muramyl dipeptide that activates macrophages to a cytolytic state in situ, significantly protected mice against lethal challenge with herpes simplex virus type 2. These findings suggest that the systemic activation of macrophages by liposomes containing an immunomodulator can lead to prophylaxis of severe infections caused by herpesviruses.

Immunostimulation in cancer patients

It is interesting to treat cancer patients by the potentiation of their depressed immune status. There are many immunopotentiators which showed potent antitumor activity in experimental tumor systems in vivo and in vitro, however, which were not always effective in well-designed controlled clinical trials. At the present time, we should say that cancer immunotherapy is not the first modality for cancer treatment and we should be careful not to miss more effective modalities for the treatment of cancer patients by the overestimation of cancer immunotherapy. Further extensive studies will be required to establish new modalities such as the development of more effective immunostimulation which is cytotoxic to tumor cells and the exploration of combined immunostimulation by using more than two immunotherapies, or immunotherapy combined with other cancer therapeutic modalities.